[Home ] [Archive]   [ فارسی ]  
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
Main Menu
Home::
Journal Information::
Articles archive::
For Authors::
For Reviewers::
Registration::
Contact us::
Site Facilities::
Ethics::
peer-review::
Indexing::
::
Search in website

Advanced Search
..
Receive site information
Enter your Email in the following box to receive the site news and information.
..
Journal DOI

AWT IMAGE

..
Copyright Policy
This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 
This Journal is licensed under a Creative Commons Attribution-NonCommercial 4.0
..
:: Volume 19, Issue 10 (10-2017) ::
J Babol Univ Med Sci. 2017; Volume 19 Back to browse issues page
Anti-Cancer Effect of Aprepitant on Nb4 Leukemic Cells
E Razani , S Bayati , A Safaroghli Azar , D Bashash * , AH Ghafari
Department of Hematology and Blood Bank, Facuty of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, I.R.Iran , David_5980@yahoo.com
Abstract:   (4804 Views)

BACKGROUND AND OBJECTIVE: Genetic studies have demonstrated that the neurokini-1 Receptor (NK1R (is frequently involved in the pathogenesis of wide assortment of human malignancies, including acute promyelocytic leukemia (APL). The activity of this pathway in leukemic cells results in an excessive cell proliferation and evade from apoptosis. In this study, we aimed to investigate the effect of Aprepitant (NK1R antagonist) on the survival rate of APL cells.
METHODS: This experimental study is conducted on APL-derived NB4 cells (Institute Pasteur). To determine the anti-tumor effect of Aprepitant, NB4 cells were divided into 6 groups: control and 1-, 2-, 3-, 4- and 5 µM-drug treated groups. Then the cell viability, metabolic activity, induction of apoptosis and transcriptional alteration of Bax and Bcl-2 genes were investigated after 24 and 36 h treatment using trypan blue assay, MTT assay, Annexin-V/PI staining and RQ-PCR analysis, respectively.
FINDINGS: 36 h treatment with the highest concentration of Aprepitant (5 µM) resulted in an approximately 50% reduction in the viability (assessed by trypan blue) and metabolic activity (assessed by MTT assay) of NB4 cells (p<0.001) in comparison with control group. Moreover, Aprepitant is able to increase the proportion apoptotic cells from 1.4% in control group to 10.6% in 5 µM drug-treated cells though up-regulating Bax/Bcl-2 molecular ratio (p≤0.05).
CONCLUSION: Aprepitant exerted both cytotoxic and anti-proliferative effects in NB4 cells.

 

Keywords: Acute promyelocytic leukemia, Apoptosis, Aprepitant, NB4 cell line
Full-Text [PDF 426 kb]   (1341 Downloads)    
Type of Study: Experimental | Subject: Hematology
Received: 2017/06/25 | Accepted: 2017/10/11 | Published: 2017/10/31
Send email to the article author


XML   Persian Abstract   Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Razani E, Bayati S, Safaroghli Azar A, Bashash D, Ghafari A. Anti-Cancer Effect of Aprepitant on Nb4 Leukemic Cells. J Babol Univ Med Sci 2017; 19 (10) :28-34
URL: http://jbums.org/article-1-6924-en.html


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 19, Issue 10 (10-2017) Back to browse issues page
مجله علمی دانشگاه علوم پزشکی بابل Journal of Babol University of Medical Sciences

The Journal of Babol University of Medical Sciences is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Persian site map - English site map - Created in 0.06 seconds with 43 queries by YEKTAWEB 4645